Actively Recruiting
Study of Venetoclax Resistance in Adults With Chronic Lymphocytic Leukemia Examining Resistance Mechanisms After Venetoclax Treatment
Led by University Hospital, Clermont-Ferrand · Updated on 2024-01-09
50
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying refractory andor relapsed chronic lymphocytic leukemia CLL in patients who have been treated with venetoclax. The study aims to collect medical information and samples to evaluate how often resistance to venetoclax develops, focusing on factors such as BCL2 gene mutations, over-expression of related proteins, and changes in energy metabolism. Participants with refractory or relapsed CLL during or after venetoclax treatment will provide blood, bone marrow, andor lymph node samples. This observational study follows a cohort of such patients to analyze resistance mechanisms and their clinical and genomic correlations. During the study, researchers will measure the frequency of BCL2 gene mutations and other resistance markers immediately after CLL progression. They will also examine clinical and genomic features related to resistance and track progression-free survival. The study is sponsored by the University Hospital, Clermont-Ferrand, and runs until March 2027.
CONDITIONS
Brief Title
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Research Team
L
Lise Laclautre
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
